---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-079597"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:27:36.773997+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Invivyd reports FY2023 net loss $198.6M; obtains EUA for PEMGARDA COVID-19 PrEP

## Summary
- Net loss $198.6M ($1.81/share) vs $241.3M ($2.23/share) in 2022; R&D expenses $163.6M.
- Cash & equivalents $200.6M as of Dec 31, 2023; expects runway into Q4 2024 (excl. PEMGARDA sales).
- Received EUA on Mar 22, 2024 for PEMGARDA (pemivibart) for COVID-19 PrEP in immunocompromised patients.
- Raised $40.5M in gross proceeds from ATM facility in Feb 2024 to strengthen balance sheet ahead of launch.
- Nominated VYD2311 as next SARS-CoV-2 mAb candidate; expects streamlined FDA development pathway.

## SEC filing metadata
- accession: 0001193125-24-079597
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312524079597/0001193125-24-079597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312524079597/d803546d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-079597
- JSON: https://secwatch.observer/filing/0001193125-24-079597.json
- Plain text: https://secwatch.observer/filing/0001193125-24-079597.txt

## Key facts
- Earnings Releases
  Invivyd, Inc. reported the year ended December 31, 2023 results: net income Net loss was $198.6 million for the year ended December 31, 2023, EPS Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Net income: Net loss was $198.6 million for the year ended December 31, 2023
  - EPS: Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023
  - Result: reported results
  source text: Invivyd, Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1832038/000119312524079597/0001193125-24-079597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.